Credit Suisse Ag Bluebird Bio, Inc. Call Options Transaction History

Credit Suisse Ag

4 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 13, 2020	BUY	$34.44 - $43.75 $1.07 Million - $1.36 Million	31,000 Added 184.52%	47,800 $2.58 Million
Q2 2020 Aug 12, 2020	SELL	$27.12 - $45.97 $621,048 - $1.05 Million	-22,900 Reduced 57.68%	16,800 $1.03 Million
Q4 2019 Feb 12, 2020	BUY	$46.96 - $61.67 $1.26 Million - $1.66 Million	26,900 Added 210.16%	39,700 $3.48 Million
Q4 2018 Feb 13, 2019	BUY	$59.1 - $93.26 $756,480 - $1.19 Million	12,800 New	12,800 $1.27 Million

20.2M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $315M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.